Hungarian drugmakers take action on Rxing

8 April 2007

Two Hungarian associations of pharmaceutical producers have launched a paid advertising campaign to clear up what they call "misunderstandings related to the Ministry of Health's new regulation on prescription medicines," the economic daily Napi Gazdasag has reported (Marketletters passim).

Krisztina Szekely, one of the organizers, told reporters that the Ministry's "Get better cheaper!" communication campaign may have led patients to the conclusion that doctors are bound by new laws to prescribe the cheapest product containing the active agent required for a certain treatment or face fines. She added that producers believed that the campaign was necessary since not only the public but also doctors had misunderstood the Ministry's communication, as a lot of doctors were under the same impression.

The 25.0 million forint ($135,000) advertising campaign is aimed at reassuring patients that, if they prefer a specific product, they are entitled to ask their doctors for it. They may then prescribe it, said Ms Szekely.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight